jci.orgJohnson Controls

Go to JCI Insight About Editors Consulting Editors For authors Alerts Advertising/recruitment Subscribe Contact Current Issue Past Issues By specialty COVID-19 Cardiology Gastroenterology Immunology Metabolism Nephrology Neuroscience Oncology Pulmonology Vascular biology All... Videos Conversations with Giants in Medicine Author's Takes Reviews Reviews View all reviews... Review Series Immunotherapy in Hematological Cancers (Apr 2020) Big Data's Future in Medicine (Feb 2020) Mechanisms Underlying the Metabolic Syndrome (Oct 2019) Reparative Immunology (Jul 2019) Allergy (Apr 2019) Biology of familial cancer predisposition syndromes (Feb 2019) Mitochondrial dysfunction in disease (Aug 2018) View all review series... Collections Recently published In-Press Preview Commentaries Concise Communication Editorials Viewpoint Top read articles Clinical Medicine JCI This Month Current issue Past issues The Journal of Clinical Investigation Current issue Past issues Specialties Reviews Review series Videos Conversations with Giants in Medicine Author's Takes Collections Recently published In-Press Preview Commentaries Concise Communication Editorials Viewpoint Top read articles Journal Details About Editors Consulting Editors For authors Alerts Advertising/recruitment Subscribe Contact Please note that the JCI no longer supports your version of Internet Explorer. We recommend upgrading to the latest version of Internet Explorer , Google Chrome , or Firefox × COVID-19 article collection Read the collection of COVID-19-related articles published in the JCI. Recently published - More Norrin mediates tumor-promoting and -suppressive effects in glioblastoma via Notch and Wnt Glioblastoma multiforme (GBM) contains a subpopulation of cells, GBM stem cells (GSCs), that maintain the bulk tumor and represent a key therapeutic target. Norrin is a Wnt ligand that binds... Published May 11, 2020; First published March 17, 2020 Research Article Oncology Stem cells Norrin mediates tumor-promoting and -suppressive effects in glioblastoma via Notch and Wnt Text PDF Abstract Glioblastoma multiforme (GBM) contains a subpopulation of cells, GBM stem cells (GSCs), that maintain the bulk tumor and represent a key therapeutic target. Norrin is a Wnt ligand that binds Frizzled class receptor 4 (FZD4) to activate canonical Wnt signaling. Although Norrin, encoded by NDP, has a well-described role in vascular development, its function in human tumorigenesis is largely unexplored. Here, we show that NDP expression is enriched in neurological cancers, including GBM, and its levels positively correlated with survival in a GBM subtype defined by low expression of ASCL1, a proneural factor. We investigated the function of Norrin and FZD4 in GSCs and found that it mediated opposing tumor-suppressive and -promoting effects on ASCL1lo and ASCL1hi GSCs. Consistent with a potential tumor-suppressive effect of Norrin suggested by the tumor outcome data, we found that Norrin signaling through FZD4 inhibited growth in ASCL1lo GSCs. In contrast, in ASCL1hi GSCs Norrin promoted Notch signaling, independently of WNT, to promote tumor progression. Forced ASCL1 expression reversed the tumor-suppressive effects of Norrin in ASCL1lo GSCs. Our results identify Norrin as a modulator of human brain cancer progression and reveal an unanticipated Notch-mediated function of Norrin in regulating cancer stem cell biology. This study identifies an unanticipated role of Norrin in human brain cancer progression. In addition, we provide preclinical evidence suggesting Norrin and canonical Wnt signaling as potential therapeutic targets for GBM subtype–restricted cancer stem cells. Authors Ahmed El-Sehemy, Hayden Selvadurai, Arturo Ortin-Martinez, Neno Pokrajac, Yasin Mamatjan, Nobuhiko Tachibana, Katherine Rowland, Lilian Lee, Nicole Park, Kenneth Aldape, Peter Dirks, Valerie A. Wallace × PIK3C δ expression by fibroblasts promotes triple-negative breast cancer progression As there is growing evidence for the tumor microenvironment’s role in tumorigenesis, we investigated the role of fibroblast-expressed kinases in triple-negative breast cancer (TNBC). Using a... Published May 11, 2020; First published March 10, 2020 Research Article Cell biology Oncology PIK3C δ expression by fibroblasts promotes triple-negative breast cancer progression Text PDF Abstract As there is growing evidence for the tumor microenvironment’s role in tumorigenesis, we investigated the role of fibroblast-expressed kinases in triple-negative breast cancer (TNBC). Using a high-throughput kinome screen combined with 3D invasion assays, we identified fibroblast-expressed PIK3Cδ (f-PIK3Cδ) as a key regulator of cancer progression. Although PIK3Cδ was expressed in primary fibroblasts derived from TNBC patients, it was barely detectable in breast cancer (BC) cell lines. Genetic and pharmacological gain- and loss-of-function experiments verified the contribution of f-PIK3Cδ in TNBC cell invasion. Integrated secretomics and transcriptomics analyses revealed a paracrine mechanism via which f-PIK3Cδ confers its protumorigenic effects. Inhibition of f-PIK3Cδ promoted the secretion of factors, including PLGF and BDNF, that led to upregulation of NR4A1 in TNBC cells, where it acts as a tumor suppressor. Inhibition of PIK3Cδ in an orthotopic BC mouse model reduced tumor growth only after inoculation with fibroblasts, indicating a role of f-PIK3Cδ in cancer progression. Similar results were observed in the MMTV-PyMT transgenic BC mouse model, along with a decrease in tumor metastasis, emphasizing the potential immune-independent effects of PIK3Cδ inhibition. Finally, analysis of BC patient cohorts and TCGA data sets identified f-PIK3Cδ (protein and mRNA levels) as an independent prognostic factor for overall and disease-free survival, highlighting it as a therapeutic target for TNBC. Authors Teresa Gagliano, Kalpit Shah, Sofia Gargani, Liyan Lao, Mansour Alsaleem, Jianing Chen, Vasileios Ntafis, Penghan Huang, Angeliki Ditsiou, Viviana Vella, Kritika Yadav, Kamila Bienkowska, Giulia Bresciani, Kai Kang, Leping Li, Philip Carter, Graeme Benstead-Hume, Timothy O’Hanlon, Michael Dean, Frances M.G. Pearl, Soo-Chin Lee, Emad A. Rakha, Andrew R. Green, Dimitris L. Kontoyiannis, Erwei Song, Justin Stebbing, Georgios Giamas × S100A8/A9 regulates CD11b expression and neutrophil recruitment during chronic tuberculosis Neutrophil accumulation is associated with lung pathology during active tuberculosis (ATB). However, the molecular mechanism or mechanisms by which neutrophils accumulate in the lung and contribute... Published May 11, 2020; First published March 5, 2020 Research Article Immunology Infectious disease S100A8/A9 regulates CD11b expression and neutrophil recruitment during chronic tuberculosis Text PDF Abstract Neutrophil accumulation is associated with lung pathology during active tuberculosis (ATB). However, the molecular mechanism or mechanisms by which neutrophils accumulate in the lung and contribute to TB immunopathology are not fully delineated. Using the well-established mouse model of TB, our new data provide evidence that the alarmin S100A8/A9 mediates neutrophil accumulation during progression to chronic TB. Depletion of neutrophils or S100A8/A9 deficiency resulted in improved Mycobacterium tuberculosis (Mtb) control during chronic but not acute TB. Mechanistically, we demonstrate that, following Mtb infection, S100A8/A9 expression is required for upregulation of the integrin molecule CD11b specifically on neutrophils, mediating their accumulation during chronic TB disease. These findings are further substantiated by increased expression of S100A8 and S100A9 mRNA in whole blood in human TB progressors when compared with nonprogressors and rapidly decreased S100A8/A9 protein levels in the serum upon TB treatment. Furthermore, we demonstrate that S100A8/A9 serum levels along with chemokines are useful in distinguishing between ATB and asymptomat...